Item 8.01 Other Events.

On January 23, 2021, Osmotica Pharmaceuticals plc (the "Company") submitted a Type A meeting request to the U.S. Food and Drug Administration ("FDA") to discuss the FDA's Complete Response Letter in connection with the Company's New Drug Application (the "NDA") for arbaclofen ER tablets for the alleviation of spasticity in multiple sclerosis and the CRL's recommendations and obtain advice on a path forward for the NDA.

© Edgar Online, source Glimpses